Samantha Neves
Research Subjects
Samantha Neves has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Ramacciotti
Science Valley Research Institute, Brasil; Loyola University Medical Center, EUA
4 shared publications - Flávia Magalhães Silveira Magella Oliveira
Instituto de Infectologia Emílio Ribas
2 shared publications - Isabela Zampirolli Leal
Santa Casa de São Paulo School of Medical Sciences, São Paulo, SP, Brazil
2 shared publications - Nelson Wolosker
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2 shared publications - Rebeca Higino Becker
Faculdade de Ciencias Medicas da Santa Casa de Misericordia de Sao Paulo
2 shared publications Roberto Augusto Caffaro
Santa Casa de Sao Paulo School of Medical Sciences
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24
Primary hyperhidrosis: from sweat physiology to a proposed diagnostic-therapeutic algorithm
- 5 November 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24
Open AccessPrimary hyperhidrosis: from sweat physiology to a proposed diagnostic-therapeutic algorithm
- 20 August 2026
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
Spot size variation and skin interaction of long-pulse 1064nm Nd: YAG laser used for varicose veins treatment: A prospective, randomized, assessor-blinded ex vivo study
Background: Long-pulsed Nd: YAG 1064 lasers are the standard of care for superficial vein transcutaneous laser treatment. The current concept suggests that the larger the laser spot size, the deeper the penetration into the skin for two reasons: First, wider spot sizes allow the use of higher pulse energy, as energy density (Fluence) decreases exponentially as the beam area widens. Second, the same pulse energy delivered by a smaller beam will be concentrated in the surface owing to the scattering effect. In this study, we examine the effect on skin penetration by changing the spot size of a long-pulsed Nd: YAG 1064 nm laser. Methods: 100 different skin samples from 5 human dermolipectomy flaps were shot with 3 consecutive long-pulsed Nd: YAG 1064 nm pulses, one of each with a different spot size (3, 5, and 7 mm), while an energy meter was placed underneath to measure energy. In the first 80 samples, the same total energy (10J) was used for all 240 shots. In the last 20 samples, the same energy density (Fluence) of 100 J/cm2 was used in all 60 shots. Results: No variations in mean energy across all spot sizes were observed (3 mm = 3.85 ± 0.89 J, 5 mm = 4.15 ± 0.83 J, 7 mm = 3.96 ± 0.73 J, p = 0.072). Regardless of the spot size, the average pulse energy attenuation was 60.1% with a standard deviation of 8.3%. The average fluence attenuation was 52.3% with a standard deviation of 5.7%. A strong correlation was found in the final energy measured in the same area, regardless of the spot size used. Conclusion: In an ex vivo human skin model, varying the spot size of a long-pulsed Nd: YAG 1064 nm laser did not significantly affect energy transmission to the subdermal tissue.
- 20 August 2026
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
Spot size variation and skin interaction of long-pulse 1064nm Nd: YAG laser used for varicose veins treatment: A prospective, randomized, assessor-blinded ex vivo study
Background: Long-pulsed Nd: YAG 1064 lasers are the standard of care for superficial vein transcutaneous laser treatment. The current concept suggests that the larger the laser spot size, the deeper the penetration into the skin for two reasons: First, wider spot sizes allow the use of higher pulse energy, as energy density (Fluence) decreases exponentially as the beam area widens. Second, the same pulse energy delivered by a smaller beam will be concentrated in the surface owing to the scattering effect. In this study, we examine the effect on skin penetration by changing the spot size of a long-pulsed Nd: YAG 1064 nm laser. Methods: 100 different skin samples from 5 human dermolipectomy flaps were shot with 3 consecutive long-pulsed Nd: YAG 1064 nm pulses, one of each with a different spot size (3, 5, and 7 mm), while an energy meter was placed underneath to measure energy. In the first 80 samples, the same total energy (10J) was used for all 240 shots. In the last 20 samples, the same energy density (Fluence) of 100 J/cm2 was used in all 60 shots. Results: No variations in mean energy across all spot sizes were observed (3 mm = 3.85 ± 0.89 J, 5 mm = 4.15 ± 0.83 J, 7 mm = 3.96 ± 0.73 J, p = 0.072). Regardless of the spot size, the average pulse energy attenuation was 60.1% with a standard deviation of 8.3%. The average fluence attenuation was 52.3% with a standard deviation of 5.7%. A strong correlation was found in the final energy measured in the same area, regardless of the spot size used. Conclusion: In an ex vivo human skin model, varying the spot size of a long-pulsed Nd: YAG 1064 nm laser did not significantly affect energy transmission to the subdermal tissue.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20250108
Evaluation of a clinical score to predict post-sclerotherapy hyperpigmentation compared with the Skin Hyperpigmentation Index: a prospective Skin Code study
Post-sclerotherapy hyperpigmentation (PSH) is a common complication following sclerotherapy for telangiectasias and reticular veins. However, tools for pre-procedural prediction of PSH are limited, making pre-treatment identification of patients at greater risk a challenge. This research aimed to evaluate a clinical scoring system (Skin Code Score) designed to estimate the individual risk of PSH. A prospective, single-center, single-arm study was conducted. Adult female patients with telangiectasias and reticular veins were treated and evaluated for pigmentation risk using the Skin Code Score (range, 2-12 points). Hyperpigmentation was assessed at baseline and on day 30 by in-person evaluation performed by one vascular surgeon, complemented by photographic analysis conducted independently by two other vascular surgeons and one dermatologist. Skin Hyperpigmentation Index (SHI) measurements were used for objective correlation with the Skin Code Score. The Skin Code Score showed strong interobserver agreement and reproducibility (κ ≥ 0.85). Diagnostic accuracy ranged from 82.8% to 94.7% among evaluators. A score of 12 predicted PSH in up to 99.8% of cases, while a score of 8 indicated a probability of approximately 76%. The study was limited by a small sample size and its single-center design; a proportion of the assessments were conducted by photographic analysis. It is concluded that the Skin Code Score is a simple and reproducible tool for predicting PSH and could assist clinicians with pre-procedural risk stratification, patient counseling, and clinical decision-making.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20250108
Open AccessEvaluation of a clinical score to predict post-sclerotherapy hyperpigmentation compared with the Skin Hyperpigmentation Index: a prospective Skin Code study
Post-sclerotherapy hyperpigmentation (PSH) is a common complication following sclerotherapy for telangiectasias and reticular veins. However, tools for pre-procedural prediction of PSH are limited, making pre-treatment identification of patients at greater risk a challenge. This research aimed to evaluate a clinical scoring system (Skin Code Score) designed to estimate the individual risk of PSH. A prospective, single-center, single-arm study was conducted. Adult female patients with telangiectasias and reticular veins were treated and evaluated for pigmentation risk using the Skin Code Score (range, 2-12 points). Hyperpigmentation was assessed at baseline and on day 30 by in-person evaluation performed by one vascular surgeon, complemented by photographic analysis conducted independently by two other vascular surgeons and one dermatologist. Skin Hyperpigmentation Index (SHI) measurements were used for objective correlation with the Skin Code Score. The Skin Code Score showed strong interobserver agreement and reproducibility (κ ≥ 0.85). Diagnostic accuracy ranged from 82.8% to 94.7% among evaluators. A score of 12 predicted PSH in up to 99.8% of cases, while a score of 8 indicated a probability of approximately 76%. The study was limited by a small sample size and its single-center design; a proportion of the assessments were conducted by photographic analysis. It is concluded that the Skin Code Score is a simple and reproducible tool for predicting PSH and could assist clinicians with pre-procedural risk stratification, patient counseling, and clinical decision-making.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20250065
Topical oxybutynin antiperspirant for axillary hyperhidrosis: a phase IIb PROBE design clinical trial (TODAY trial)
Background Primary hyperhidrosis is a chronic condition with limited therapeutic options. Objectives To evaluate the impact of 10% oxybutynin spray on axillary hyperhidrosis, considering both its local and systemic effects, in terms of Hyperhidrosis Disease Severity Scale (HDSS) outcomes for hyperhidrosis of the axilla and eight additional sites. Methods Prospective phase II PROBE design trial. Adult patients with axillary hyperhidrosis were randomized to receive a 10% oxybutynin topical spray, oral oxybutynin, or placebo spray for 35 days. Efficacy was evaluated on day 35 using the HDSS and a hyperhidrosis-specific quality-of-life (QoL) assessment questionnaire. Results 17 patients were randomized. No significant differences were observed in HDSS outcomes from baseline to day 35 in any of the three groups (2.5 [2 - 4], 4 [3 - 4], 3.5 [3 - 4], p= 0.207), although a trend to improvement was noted in both treatment groups. Significant improvement in the QoL questionnaire was observed from baseline to day 35 in the oxybutynin spray group (pre-intervention QoL: 78.5 [70 - 96] and post-intervention QoL: 38.5 [32 - 67], p = 0.031). Conclusions No differences were observed in the primary outcome. A significant improvement from baseline to day 35 was observed in the QoL questionnaire score for the oxybutynin spray group.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20250065
Open AccessTopical oxybutynin antiperspirant for axillary hyperhidrosis: a phase IIb PROBE design clinical trial (TODAY trial)
Background Primary hyperhidrosis is a chronic condition with limited therapeutic options. Objectives To evaluate the impact of 10% oxybutynin spray on axillary hyperhidrosis, considering both its local and systemic effects, in terms of Hyperhidrosis Disease Severity Scale (HDSS) outcomes for hyperhidrosis of the axilla and eight additional sites. Methods Prospective phase II PROBE design trial. Adult patients with axillary hyperhidrosis were randomized to receive a 10% oxybutynin topical spray, oral oxybutynin, or placebo spray for 35 days. Efficacy was evaluated on day 35 using the HDSS and a hyperhidrosis-specific quality-of-life (QoL) assessment questionnaire. Results 17 patients were randomized. No significant differences were observed in HDSS outcomes from baseline to day 35 in any of the three groups (2.5 [2 - 4], 4 [3 - 4], 3.5 [3 - 4], p= 0.207), although a trend to improvement was noted in both treatment groups. Significant improvement in the QoL questionnaire was observed from baseline to day 35 in the oxybutynin spray group (pre-intervention QoL: 78.5 [70 - 96] and post-intervention QoL: 38.5 [32 - 67], p = 0.031). Conclusions No differences were observed in the primary outcome. A significant improvement from baseline to day 35 was observed in the QoL questionnaire score for the oxybutynin spray group.
- 4 September 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 41 (5) , 410-418
Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial)
Background: Sclerotherapy with polidocanol is the gold standard treatment for telangiectasias and varicose veins, but technologies such as transdermal radiofrequency are also available. Transdermal radiofrequency (V Eraser ®) , a device that combines transdermal radiofrequency and sclerotherapy, was developed to treat these conditions. Methods: This was a prospective, randomized, and comparative study between transdermal radiofrequency and sclerotherapy for treating telangiectasias and reticular veins. Forty-one patients were randomized to either transdermal radiofrequency plus polidocanol sclerotherapy or polidocanol sclerotherapy alone and underwent a single treatment session. Efficacy was assessed using vessel clearance analysis in pre- and post-treatment images and the Aberdeen Varicose Vein Questionnaire. Results: Forty-six patients were enrolled. Both treatments significantly reduced vessel length in a single session ( p < .001). Sclerotherapy showed an average reduction of 30.7%, while transdermal radiofrequency reduced it by 33%, with no statistically significant difference ( p = .596). Quality of life improved, with pain reduction in 40% and 55% of patients in the right and left lower limbs, respectively ( p = .030 and p = .002). Conclusion: Transdermal radiofrequency was not superior to standard of care polidocanol sclerotherapy. Both methods improved quality of life, particularly in reducing pain associated with varicose veins.
- 4 September 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 41 (5) , 410-418
Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial)
Background: Sclerotherapy with polidocanol is the gold standard treatment for telangiectasias and varicose veins, but technologies such as transdermal radiofrequency are also available. Transdermal radiofrequency (V Eraser ®) , a device that combines transdermal radiofrequency and sclerotherapy, was developed to treat these conditions. Methods: This was a prospective, randomized, and comparative study between transdermal radiofrequency and sclerotherapy for treating telangiectasias and reticular veins. Forty-one patients were randomized to either transdermal radiofrequency plus polidocanol sclerotherapy or polidocanol sclerotherapy alone and underwent a single treatment session. Efficacy was assessed using vessel clearance analysis in pre- and post-treatment images and the Aberdeen Varicose Vein Questionnaire. Results: Forty-six patients were enrolled. Both treatments significantly reduced vessel length in a single session ( p < .001). Sclerotherapy showed an average reduction of 30.7%, while transdermal radiofrequency reduced it by 33%, with no statistically significant difference ( p = .596). Quality of life improved, with pain reduction in 40% and 55% of patients in the right and left lower limbs, respectively ( p = .030 and p = .002). Conclusion: Transdermal radiofrequency was not superior to standard of care polidocanol sclerotherapy. Both methods improved quality of life, particularly in reducing pain associated with varicose veins.